Translational Development Acquisition Corp. 8-K

What Happened

• Translational Development Acquisition Corp. announced on June 17, 2026 that shareholders approved amendments to its charter and trust agreement to extend the deadline to complete a business combination. The Company and Continental Stock Transfer & Trust Company (trustee) executed the Trust Agreement Amendment the same day.
• The amendments allow the Company to extend the original June 24, 2026 deadline up to twelve (12) one-month extensions — moving the deadline out to June 24, 2027 — by providing five days’ notice to the trustee and depositing the required funds into the trust account two days before each extension.

Key Details

• Extension period: up to 12 one‑month extensions, cumulatively to June 24, 2027.
• Extension cost per month: the lesser of $200,000 and $0.03 per outstanding public share, paid into the trust account two days prior to each extension; five days’ advance notice to the trustee is required.
• Shareholder vote at the June 17, 2026 meeting: For 16,621,609; Against 809,296; Abstentions 0; quorum present (17,430,905 shares, ~79.56% of 21,907,500 outstanding).
• Redemptions: Holders of 2,598,697 Class A shares redeemed at ≈ $10.70/share for an aggregate of ≈ $27,817,433.95. After redemptions, 14,651,303 Class A shares remain outstanding.

Why It Matters

• The company now has up to 12 additional months to find and close a business combination, which delays a final outcome for public investors but preserves the ability to complete a deal.
• Each monthly extension requires cash to be moved into the trust (reducing the trust balance available for transaction or redemption), and past redemptions already withdrew ≈ $27.8M from the trust. Investors should note the extended timeline, the recurring deposit requirement, and the reduced public float when assessing future liquidity or deal prospects.
• No target business combination was announced in this filing; the actions are procedural steps to extend the SPAC’s life.